Immune Checkpoint Inhibition by Anti-Pdcd1 (Anti-Pd1) Monoclonal Antibody Has Significant Therapeutic Activity Against Central Nervous System Lymphoma in an Immunocompetent Preclinical Model

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15009
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Anti-Tumor Activity of an Anti-Endoglin Monoclonal Antibody Is Enhanced in Immunocompetent Mice

International Journal of Cancer
Cancer ResearchOncology
2008English

Preclinical Antilymphoma Activity of a Humanized Anti-Cd40 Monoclonal Antibody, SGN-40

Cancer Research
Cancer ResearchOncology
2005English

Anti-Antibody Activity of a Monoclonal Macroglobulin

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1971English

Central Nervous System Aspergillosis in an Immunocompetent Patient

Journal of Infection in Developing Countries
MedicineVirologyParasitologyInfectious DiseasesMicrobiology
2011English

An Adapted Anti-Ctla4 Therapeutic Aimed at Mitigating the Toxicities of Checkpoint Inhibition

Journal of Clinical Investigation
Medicine
2018English

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

Cancer immunology research
Cancer ResearchImmunology
2015English

Pd-1 Immune Checkpoint Blockade Improves Anti-Cd20 Based Immunotherapy in Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Therapeutic Effect of Anti-Nucleokine Monoclonal Antibody on Ischemic Brain Infarction

Yakugaku Zasshi
PharmacologyPharmaceutical Science
2009English

LY3009120, a panRAF Inhibitor, Has Significant Anti-Tumor Activity in BRAF and KRAS Mutant Preclinical Models of Colorectal Cancer

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy